Tweet
Adimmune Corporation, a Taiwan-based vaccine developer, recently announced the successful completion of a Phase III clinical trial on an H7N9 influenza vaccine developed from a World Health Organization-approved virus strain.
An Adimmune company spokesperson said the company has the ability to produce three million units of preliminary H7N9 vaccines each month. In April, Steve Chan, the chairman of Adimmune, said the vaccine could be ready by May for clinical trials, AsianScientist reports.
..
An Adimmune company spokesperson said the company has the ability to produce three million units of preliminary H7N9 vaccines each month. In April, Steve Chan, the chairman of Adimmune, said the vaccine could be ready by May for clinical trials, AsianScientist reports.
..
